Previous 10 | Next 10 |
Travere Therapeutics Inc. (NASDAQ:TVTX) traded at a new 52-week low today of $14.08. This new low was reached on below average trading volume as 130,000 shares traded hands, while the average 30-day volume is approximately 738,000 shares. Based on a current price of $14.15, Travere Thera...
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a ...
The stock of Travere Therapeutics (NASDAQ: TVTX) was on the decline by almost 17% in midafternoon trading Wednesday. That was on the back of dispiriting regulatory news from the rare-disease biotech. Travere disclosed that the Food and Drug Administration won't grant accelerat...
Gainers: Owens & Minor (OMI) +25%.Express (EXPR) +23%.PDL Community Bancorp (PDLB) +22%.Takung Art (TKAT) +22%.Assertio Holdings (ASRT) +21%.Asensus Surgical (ASXC) +20%.Lizhi (LIZI) +20%.ReneSola (SOL) +19%.Arcimoto (FUV) +18%.Planet Green (PLAG) +16%.Losers: Lar...
Agilent price target raised by analysts after better than expected Q2 resultsSeveral firms have lifted the price target for Agilent Technologies (A) after the company raised the fiscal 2021 guidance and reported better-than-expected Q2 FY21 earnings. Agilent has added ~5.1% in ...
Larimar Therapeutics (LRMR) -40% after FDA puts clinical hold on CTI-1601 program.GSX Techedu (GOTU) -15% after Q1 earnings releaseCarLotz (LOTZ) -16% after losing key sourcing partner temporarily.Travere Therapeutics (TVTX) -13% on sparsentan developme...
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS). Following achievement of the interim proteinuria endpoint in the ongoing Phase 3 DUPLEX Study of ...
Analysts remain bullish on Travere despite approval of Thiola genericTravere Therapeutics (TVTX) fell sharply in mid-day trading Friday on the news of FDA approval for a Thiola (tiopronin) generic. A late recovery ensured the stock was only ~3.3% lower by the close.The Wall Street a...
Travere Therapeutics ([[TVTX]] -9.3%) has dropped sharply in morning hours after the FDA website indicated the approval for Abbreviated New Drug Application ((ANDA)) submitted by Teva Pharmaceuticals ([[TEVA]] +2.0%) for Tiopronin Tablets, 100 mg.In 2019, Travere won the FDA ap...
Travere Therapeutics, Inc. (TVTX) Q1 2021 Earnings Conference Call May 06, 2021 04:30 PM ET Company Participants Chris Cline - Vice President, Investor Relations & Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Comm...
News, Short Squeeze, Breakout and More Instantly...
Travere Therapeutics Inc Com Company Name:
TVTX Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on May 10, 2024, the Compensation Co...
2024-05-14 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly d...